



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

**June 3, 2014 6:00 – 8:15 p.m.
*** Please note new times *****

- 1. Executive Session** **6:00 - 6:15**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes** **6:15 - 6:20**
(Public Comment Prior to Board Action)

- 3. DVHA Pharmacy Administration Updates** **6:20 - 6:30**
 - Transition to new Pharmacy Benefit Manager (PBM) effective 1/1/2015
 - Updates

- 4. Medical Director Update** **6:30 - 6:35**
 - Clinical Programs Update
 - Prescriber Comments

- 5. Follow-up Items from Previous Meetings** **6:35 – 6:50**
 - Hepatitis C Medications – older agents (remove) and SVR4 with newer agents
 - Methadone – Letter to Prescribers

- 6. RetroDUR/DUR** **6:50 – 7:00**
 - Triptans for Migraine/Quantity Limits and Multiple Agents

- 7. Clinical Update: Drug Reviews** **7:00 – 7:40**
(Public comment prior to Board action)

Abbreviated New Drug Reviews

- Aerospan[®] (flunisolide HFA) Inhalation Aerosol
- Noxafil[®] (posaconazole) Oral Delayed-Release Tablet
- Otrexup[®] (methotrexate) Subcutaneous Single-Dose Auto-Injector
- Versacloz[®] (clozapine) Oral Suspension
- Zorvolex[®] (diclofenac) Oral Capsule

Full New Drug Reviews

- Fycompa[®] (perampanel) Film Coated Oral Tablets
- Opsumit[®] (macitentan) Oral Tablet

- 8. Therapeutic Drug Classes – Periodic Review** **7:40 – 7:55**
(Public comment prior to Board action)
- Fentanyl Immediate Release Products (includes review of Lazanda[®] (fentanyl nasal spray))
 - Immunomodulators (new drug formulation – Actemra[®] (tocilizumab) Subcutaneous Prefilled Syringe)
- 9. Clinical Update: New/Updated Clinical Guidelines** **7:55 – 7:55**
(Public comment prior to Board action)
- None
- 10. New Managed Therapeutic Drug Classes** **7:55 – 7:55**
(Public comment prior to Board action)
- None
- 11. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **7:55 – 8:05**
(Public comment prior to Board action)
- Analgesics: Long Acting Narcotics (new FDA language for indication)
 - Alzheimer’s Agents: Namenda[®] XR – manufacturer to discontinue Namenda[®] IR
- 12. General Announcements** **8:05– 8:15**
Selected FDA Safety Alerts
- Epidural Corticosteroid Injection: Drug Safety Communication - Risk of Rare But Serious Neurologic Problems
 - Eszopiclone Containing Sleep Aids: Drug Safety Communication - Can Cause Next-Day Impairment – Recommend 1 mg Starting Dose
 - FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin
- 13. Adjourn** **8:15**